Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Qiagen's Rotor-Gene Q MDx Platform, Influenza A/B Assay

NEW YORK (GenomeWeb News) – Qiagen today announced its real-time PCR instrument Rotor-Gene Q MDx and the artus Infl A/B RG RT-PCR kit for Influenza A/B has received 510(k) clearance from the US Food and Drug Administration.

The Rotor-Gene Q MDx instrument is an automated molecular detection platform that is intended for in vitro diagnostic use with FDA-cleared or approved nucleic acid tests in clinical laboratories. Using a centrifugal rotary design for the amplification and quantification of DNA molecules, Rotor-Gene Q MDx enables "near-perfect well-to-well thermal and optical uniformity and a fast data acquisition rate," Qiagen said.

The artus Influ A/B RG RT-PCR kit is a real-time PCR IVD test for the differential diagnosis of Influenza A and B viral infections through qualitative detection and identification. The test uses nasopharyngeal swab samples and runs on the Rotor-Gene Q MDx instrument.

Peer Schatz, CEO of Qiagen, called the FDA clearances an important milestone for the company. "The various Rotor-Gene Q models marketed by Qiagen are not only an integral part of our revolutionary lab automation platform QIAsymphony RGQ, but are also among the most widely used stand-alone molecular detection platforms worldwide," he said. "The FDA clearances now pave the way to make this market-leading assay portfolio available to clinical laboratories in the US as well."

Qiagen added that the artus Infl A/B RG RT-PCR kit is the first of a number of IVD molecular diagnostics it plans to launch on the Rotor-Gene Q MDx instrument in the US, and other PCR-based assays are either being reviewed by FDA or are being prepared for submission to the agency. Among the assays it noted are a companion diagnostic based on KRAS mutations for guiding treatments for colorectal cancer; a companion diagnostic based on EGFR mutations to guide lung cancer treatment; and an assay for the detection of cytomegalovirus.

Various versions of the Rotor-Gene Q real-time PCR cyclers are registered as medical devices in many markets outside the US, including the European Union, China, Japan, Korea, Brazil, Australia, and Russia, Qiagen said.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.